Clinical Study of Thoracoscopic Sublung Lobectomy for Stage ⅠA Non-small Cell Lung Cancer
Objective To investigate the effect of application of thoracoscopic sublung lobectomy in the treatment of stage ⅠA non-small cell lung cancer patients.Methods A total of 92 patients admitted to Yixing People's Hospital from July 2022 to December 2023 conveniently were selected as study objects,and they were divided into study group and reference group by Excel table grouping method,with 46 cases each.The reference group was treated with thora-coscopic lobectomy.The study group was given thoracoscopic sublung lobectomy.The surgical indexes,inflammatory factor levels and the occurrence of postoperative complications were compared between the two groups.Results The surgical indexes of the study group were better than those of the reference group,and the differences were statistically significant(all P<0.05).Preoperative inflammatory factor levels were compared between the two groups,and the differ-ences were not statistically significant(all P>0.05).Postoperatively,the levels of inflammatory factors in the study group were lower than those in the reference group,and the differences were statistically significant(all P<0.05).Post-operative complication rate in the study group(4.35％)were lower than in the reference group(17.39％),and the differ-ence was statistically significant(x2=4.039,P<0.05).Conclusion Compared with thoracoscopic lobectomy,thoraco-scopic sublung lobectomy has a higher application value in treating patients with stage ⅠA non-small cell lung cancer.The patients'surgical indexes and inflammatory factor levels improved,and postoperative complications were reduced,which has clinical reference value.
NETL
NSTL
万方数据
